MedTrace Logo

Effect of Pioglitazone on Portal and Systemic Hemodynamics in Patients With Advanced Cirrhosis

NCT00570622 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2008-11-25

No results posted yet for this study

Summary

The purpose of this study is to investigate the response to pioglitazone on the hepatic venous pressure gradient and peripheral vascular responsiveness to vasoconstrictors in patients with advanced (Child´s Grade B or C) cirrhosis.

Conditions

  • Cirrhosis
  • Ascites
  • Portal Hypertension

Interventions

DRUG

Pioglitazone

Patients receive 60mg of pioglitazone once a day orally for 9 days

DRUG

Placebo

Patients receive placebo once a day orally for 9 days

Sponsors & Collaborators

  • Medical University of Vienna

    lead OTHER

Principal Investigators

  • Arnulf Ferlitsch, MD · Medical University of Vienna

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-12-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • Austria

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00570622 on ClinicalTrials.gov